1. Dacie JV. The Hemolytic Anemias, Congenital and Acquired, 3rd edn, part II. London: Churchill, 1962.

2. Pirofsky B. Autoimmune hemolytic anemia and neoplasia of the reticuloendothelium. Ann Int Med 1968;68:109.

3. Jones SE. Autoimmune disorders and malignant lymphoma. Cancer 1973;31:1092.

4. May RB, Bryan JH. Autoimmune hemolytic anemia in Hodgkin's disease. J Pediatr 1976;89:428.

5. Ellis LD, Westerman MP. Autoimmune hemolytic anemia and cancer. JAMA 1965;193:962.

6. Sohier WD Jr, Juranies E, Aub JC. Hemolytic anemia, a host response to malignancy. Cancer Res 1957;17:767.

Gordon PA, Baylis PH. Tumor induced autoimmune hemolytic anemia. Br Med J 1967;1:1569. Pirofsky B. Autoimmunization and the autoimmune hamolytic anemias. Baltimore: Williams and Wilkins, 1968;236.

Spira MA, Lynch EC. Autoimmune hemolytic anemia and carcinoma: an unusual association. Am J Med 1979:67:753.

Shulman IA, Branch DR, Nelson JM et al. Autoimmune hemolytic anemia with noth cold and ward autoantibodies. JAMA 1985;253:1746. Wortman J, Rosse W, Logue G. Cold agglutinin autoimmune hemolytic anemia in nonhematologic mlignancies. Am J Hematol 1979;6:275. Dodds AJ, Klarkowski D, Cooper DA et al. In-vitro synthesis of an anti-BI cold agglutinin complicating a case of lymphoma. Am J Clin Pathol 1979;71:473. Doan C, Bouroncle BA and Wiseman BK. Idiopathic and secondary thrombocytopenic purpura. Clinical study and evalutation of 381 cases over a period of 28 years. Ann Int Med 1960;53:861. Kim HD, Boggs DR. A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer. Am J Med 1979;67:371. Kedar A, Khan AB, Mattern JQA, et al. Autoimmune diseorders complicating adolescent Hodgkin's disease. Cancer 1979;44:112. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic purpura and Hodgkin's disease: report of two cases and a review of literature. Am JMedSci 1983;280:21.

Berkman AW, Woog JJ, Rickler TS et al. Serial dter-minations of antiplatelet antibodies in a patient with Hodgkin's diseae and autoimmune thrombocytopenia. Cancer 1983:51:2057.

Bellone JD, Kunicki TJ, Aster RH. Immune throm-bocytopenica associated with carcinoma. Ann Int Med 1983;99:470.

Schwartz KA, Slichter SJ, Harker LA. Immunemediated platelet destruction and thormbocytope-nia in patients with solid tumors. Br J Haematol 1982:51:17.

Weitberg AB, Harmon DC. Autoimmune neutropenia, hemolytic anemia and reticulocytopenia in Hodgkin's disease. Ann Int Med 1984; 100:702. Hunter JD, Logue GL, Joyner JT. Autoimmune neutropenia in Hodgkin's disease. Arch Int Med 1982;142:386.

Kruskall MS, Weitzman SA, Stossel TP et al. Lymphoma with autoimmune neutropenia and hepatic sinusoidal infiltration, a syndrome. Ann Int Med 1982;97:202.

Rosenow III EC, Hurley BT. Disorders of the thymus. A review. Arch Int Med 1984; 144:763.

24. Moore HJ, Woods EL. Myasthenia gravis-associated antibodies in asymptomatic thymoma. J Thorac Car-diovasc Surg 1985;89:308.

25. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612.

26. Stertz G. Polymyositis. Berl Klin Wochenschr 1916;53:489.

27. Vesterager L, Worm AM, Thomsen K. Dermato-myositis and malignancy. Clin Exp Dermatol 1980;5:31-35.

28. Tymms KE, Webb J. Dermatopolymyotitis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985;12:11140-1148.

29. Manchul LA, Jin A, Pritchard KI, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis: a controlled study. Arch Int Med 1985;145:1835-1839.

30. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyosi-tis and malignancy: a multicenter cooperative study. Dermatológica 1990;180:212-216.

31. Sigurgeirsson B, Lindelof B, Edhag O, Assander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-367.

32. Nelson DS. Autoantiboies in cancer patients. Pathology 1977;9:155-160.

33. Burnham TK. Antinuclear antibodies in patients with malignancies. Lancet 1972;2:436-437.

34. Fairley GH. Autoantibodies in malignant disease. Br J Haematol 1972;23 (Suppl):231-234.

35. Zermosky JO, Gormy MK, Jarczewska K. Mlig-nancy associated with antinuclear antibodies. Lancet 1972;2:1035-1036.

36. Turnbull AR, Turner DTL, Fraser JD, et al. Au-toantiboides in early breast cancer: a stage related phhenomenon? Br J Cancer 1978;38:461-463.

37. Wasserman J, Glas U, Blomgren H. Autoantiboies in patients with carcinoma of breat. Correlation with prognosis. Clin Exp Immunol 1975;19:417-422.

38. Albin RJ. Malignancy associated with antinuclear antibodies. Lancet 1972;2:1253-1254.

39. Thomas PJ, Kaur JS, Aitcheson CT, et al. Antinuclear, antinucleolar, and anticytoplasmatic antibodies in patients with malignant melanoma. Cancer Res 1983;43:1372-1380.

40. Betterle C, Peserico A, Bersani G, et al. Circulating antibodies in malignant melanoma patients. Dermatológica 1979; 159:24.

41. Kiosawa K, Daemer RJ, He LF, et al. The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma. Hepatology 1985;5:548-555.

Steiner M, Klein E, Klein G. Antinuclear reactivity of sera in pateints with leukemia and other neoplastic diseases. Clin Immunol Immunopathol 1975;4:374-381.

Isenberg DA, Shoenfeld Y, Schwartz RS. Multiple serologic reactions and their relationship to clinical activity in SLE. Arthrit Rheum 1984;27:132. Kostiala AAI, Gripenberg M, Elonen E, et al. Follow-up of antiboides against single-stranded DNA in patients with haematological malignancies. Clin Exp Immunol 1985;61:15. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leukemia and Lymphoma 1992;7:117-122. Johnson PM, Faulk WP. Rheumatoid factor: its nature, specifity and production in rheumatoid arthritis. Clin Immunol Immunopathol 1976;6:414. Twomey JJ, Rossen RD, Lewis VM, et al. Rheumatoid factor and tumor-host interaction. Proc Natl Acad Sei USA 1976;73:2106-2108. Schattner A, Shani A, Talpaz M, Bentwich Z. Rheumatoid factors in the sera of patients with gastrointestinal carcinoma. Cancer 1983;52:2156-2161. Gupta NP, Malaviya AN, Singh SM. Rheumatoid factor: correlation with recurrence in transitional cell carcinoma of the bladder. J Urol 1979; 121:417^118. Poskitt TR, Poskitt PK. Lack of association of rheumatoid factor with either circulating immune complexes or tumor burden in cancer patients. Cancer 1985;55:1507-1509.

Lewis MG, Hartman D, Jerry LM. Antiboides and anti-antibodies in human malignancy: an expression of deranged immune regulation. Ann NY Acad Sei 1976;276:316.

Whitehouse JMA, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J 1971;27: 511.

Mittra I, Perlin J, Kumakoa S. Thyroid ant other autoantiboides in British and Japanese women: an epidemiological study of breast cancer. Br Med J 1976;31:257.

Youinou P, Zabbe C, Eveilland C, et al. Antiperin-uclear activity in lung carcinoma patients. Cancer Immunol 1984;18:80.

Roubinian JR, Talal N. Neoplasia, autoimmunity and the immune response. Adv Int Med 1978,23:435450.

Theofilopoulos AN. Immune complexes in cancer. N Engl J Med 1982;307:1208-1209. Talal N, Bunin JJ. Development of malignant lymphoma in the course of Sjogren's syndrome. Am J Med 1969;36:529-540.

Ghorssein NA, Boworth JL. Immunocompetence in radiation therapy patients. In Waters H ed. The

Handbook of Cancer Immunology. New York: Gerland STPM Press, 1978:180-181.

59. Shoenfeld Y, Segol G, Segol O, et al. Detection of antibodies to total histones and their subfractions in SLE patients and their asymptomatic relatives. Arthrit Rheum 1987;30:169-175.

60. Shoenfeld Y, Ben-Yehuda O, Naparstek Y, et al. The detection of a common idiotype of anti-DNA antibodies in the sera of patients with monoclonal gammopathies. J Clin Immunol 1986;6:194-204.

61. Huminer D, Tomer Y, Pitlick S, Shoenfeld Y. Autoantibodies in cancer patients: are the tumor related or age related? Autoimmunity 1990;5:232-233.

62. Swissa M, Amital-Teplizki H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer 1990;65:2554-2558.

63. Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Sem Arthrit Rheum 1988;18:77-87.

64. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-696.

65. Prior P, Symmons DPM, Hawkins CF, et al. Cancer Morbidity in rheumatoid arthirtis. Ann Rheum Dis 1984;43:128-131.

66. Symmons DPM, Ahem M, Bacon PA, et al. Lym-phoproliferative malignancy in rhumatoid arthritis: a study of 20 cases. Ann Rheum Dis 1984;43:132-135.

67. Banks PM, Witrak GA, Conn DL. Lymphoid neoplasia following connective tissue disease. Mayo Clin Proc 1979;54:104-108.

68. Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinemia in rheumatoid arthritis. Ann Rheum Dis 1991;50:290-294.

69. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-1743.

70. Zijlmans JM, van Rijthoven AW, Kluin PM, Jiwa NM, Dijkmans BA, Kluin-Nelemans JC. Epstein Barr associated lymphoma in a patient with rhumatoid arthritis treated with cyclosporin. N Engl J Med 1992;326:1363.

71. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991;18:809-814.

72. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-49.

Sulkes A, Naparstek Y. The infrequent association of systemic lupus erhthematosus and solid tumors.

Cancer 1991;68:1389-1393.

Houssiau FA, Kirkove C, Asherson RA, Hughes

GR, Timothy AR. Malignant lymphoma in systemic rheumatic diseases. A report of five cases. Clin Exp

Rheumatol 1991;9:515-518.

Canoso JJ, Cohen AS. Malignancy in a series of 70

patients with systemic lupus erhthematosus. Arthrit

Rheum 1974;17:383-390.

Black RA, Zilko PJ, Dawkins PI, et al. Cancer in connective tissue disease. Arthrit Rheum 1982;25:1130-1133.

Mellous RC. Autoimmune and immunoproliferative disease of NZBAV mice and hybrids. Int Rev Exp Pathol 1966;5:217-219.

Berliner J, Shoenfeld Y, Sidi Y, et al. Systemic lupus erythematosus and lymphoma. Scand J Rheumatol 1983;12:310-314.

Kaji T, Inose K, Tsuchida A, Andoh K, Ohkubo Y, Ono K, Murakami H, Yano S, Omine M, Naruse T, et al. T-zone lymphoma in association with systemic lupus erythematosus. J Med 1991;22:225-241. Tsusumi Y, Deng YL, Uchiyama M, Kawano K, Ikeda Y. OPD4-positive T-cell lymphoma of the liver in systemic lupus erythematosus. Acta Pathol Jpn 1991;41:829-833.

Green JA, Dawson AA, Walker W. Systemic lupus erythematosus and lymphoma. Lancet 1978;2:753-755.

Bunim Jj, Talal N. Development of malignant lymphoma in the course of Sjogren's syndrome. Trans Assoc Am Physicians 1963:76:45^6. Kassan SS, Thomas TL, Moutsopoulus HM, et al. Increased risk of lymphoma in Sicca Syndrome. Ann Int Med 1978;89:888-892.

Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, Blair GS, Howe J, Dick WC, Griffiths ID. Primary Sjogren's syndrome in north east England— a longitudinal study. Br J Rheumatol 1991;30:437-442.

Takagi N, Nakamura S, Yamamoto K, Kunishma K, Takagi I, Suyama M, Shinoda M, Sugiura T, Oyama A, Suzuki H, et al. Malignant lymphoma of mucosa-associated lymphoid tissue arising in the thymus of a patient with Sjogren's syndrome. A morphologic, phenotypic, and genotypic study. Cancer 1992;69:1347-1355.

Ngan BY, Warnke RA, Wilson M, Takagi K, Cleary ML, Dorfman RF. Monocytoid B-cell lymphoma: a study of 36 cases. Hum Pathol 1991;22:409-421.

Chevalier X, Gaulard P, Voisin MC, Martigny J, Farcet JP, Larget-Piet B. Peripheral T cell lymphoma with Sjogren's syndrome: a report with immunologic and genotypic studies. J Rheumatol 1991; 18:1744— 1746.

88. Fox RI, Luppi M, Kang HI, Pisa P. Reactivation of Epstein-Barr virus in Sjogren's syndrome. Springer Semin Immunopathol 1991;13:217-231.

89. Pisa EK, Pisa P, Kang HI, Fox RI. High frequency of t(14:18) translocation in salivary gland lymphomas from Sjogren's syndrome patients. J Exp Med 1991;174:1245-1250. 90.Williams RC. Deram-tomyositis and malignancy—a review of the literature. Ann Int Med 1959 ;50:1174-1181.

90. Barnes BE. Deramtomyositis and malignancy—a review of the literature. Ann Int Med 1976;84:68-76.

91. Callen JP. Dermatomyositis and malignancy. Clin Rheum Dis 1982;8:369-387.

92. Schwarzer AC, Schrieber L. Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 1991;3:145-154.

93. Christiansen HB, Brunspry LA, Perry HO. Drmato-myositis: unusual features, complications and treatment. Arch Dermatol 1956;74:581-589.

94. Manchul LA, Jin A, Pritchard KI, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Int Med 1985;145:1835-1839.

95. Bohan A, Peter JB. Polymyostis and dermatomyositis. N Engl J Med 1975;292:344-347, 403407.

96. Sattar MA, Guindi RT, Khan RA, Tungekar MF. Polymyositis and hepatocellular carcinoma. Clin Rheumatol 1988;7:538-542.

97. Rivers JK, Shaw HM, Milton GW, McCarthy WH. Polymyositis in association with melanoma. Arch Dermatol 1990;126:686-687.

98. Landa NG, Zelickson BD, Kurtin PJ, Winkelmann RK. Primary B-cell lymphoma with histologic features of a T-cell neoplasm. J Am Acad Dermatol 1992;26:288-292.

99. Schulman P, Kerr LD, Spiera H. A reexamination of the relationship between myositis and malignancy. J Rheumatol 1991;18:1689-1692.

100. Zatuchini J, Campbell WN, Zarafonetis CJD. Pulmonary fibrosis and terminal bronchiolar ("alveolar cell") carcinoma in scleroderma. Cancer 1953;6:1147-1158.

101. Jones AW. Alveolar cell carcinoma occuring in ideo-pathic interstitial pulmonsry fibrosis. Br J Dis Chest 1970;64:78-84.

102. Fraire AE, Greenberg SD. Carcinoma and diffuse interstitial fibrosis of lung. Cancer 1973;31:1078— 1086.

103. Duncan SC, Winkelman RR. Cancer and scleroderma. Arch Dermatol 1979;115:950-955.

104. Peter-Golden M, Wise RA, Hochberg M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985;12:1136-1139.

105. Roumm AD, Medsger TA. Cancer and systemic sclerosis. Arthrit Rheum 1985;28:1336-1340.

106. Talbott JH, Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgeno-graphic changes in two cases. Semin Arthrit Rheum 1980;9:191-216.

107. Black RA, Zilko PJ, Dawkins PL, et al. Cancer in connective tissue disease. Arthrit Rheum 1982;25:1130-1133.

108. Hamburger JL, Miller JM, Kini SR. Lymphoma of the thyroid. Ann Int Med 1983;99:685-693.

109. Devine RM, Edis AJ, Banks PM. Primary lymphoma of the thyroid: a review of the Mayo Clinic experience through 1978. World J Surg 1981;5:33-38.

110. Aozasa K, Tajima K, Tominaga N, Katagiri S, Yonezawa T, Matsuzuka F, Kuma K, Sawada M. Immunologic and immunohistochemical studies on chronic lymphocytic thyroiditis with or without thyroid lymphoma. Oncology 1991;48:65-71.

111. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyrodiditis. N Engl J Med 1985;312:601-604.

112. Moskowitz C, Dutcher JP, Wiernik PH. Association of thyroid disease with acute leukemia. Am J Hematol 1992;39:102-107.

113. Shoenfeld Y, Schwartz RS. Immunologic and genetic factors in autoimmune diseases. N Engl J Med 1984;311:1019-1023.

114. Seggev JS, Ben-Yosef N, Meytes D. Is selective IgA deficiency associated with morbidity? review and réévaluation. Isr J Med Sei 1988;24:65-69.

115. Tomer Y, Shoenfeld Y. The significance of T suppressor cells in the development of autoimmuntiy. J Autoimmunity 1989;2:739-758.

116. Primi D, Hammarstrom L, Smith CIE. Genetic control of lymphocyte defect I. Lack of suppression in aged NZB mice is due to a B cell defect. J Immunol 1978;121:2241-2243.

117. Klinnan DM, Mushinsky JF, Steinberg AD. Oncogene expression in systemic lupus erythematosus (abstr). Clin Res 1985;33:558A.

118. Boumpas DT, Tsokus GC, Mann DL, et al. Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune disease. Arthrit Rheum 1986;29:755-760.

© 2000 Elsevier Science B.V. All rights reserved. Cancer and Autoimmunity Y. Shoenfeld and M. E. Gershwin, editors

Smoking Solutions

Smoking Solutions

How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution. Get All The Support And Guidance You Need To Be A Success At Quitting Smoking. This Book Is One Of The Most Valuable Resources In The World When It Comes To How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution.

Get My Free Ebook

Post a comment